Hot Safest Stocks To Watch For 2014

Shares of Kimberly-Clark (KMB) were rising 1.4% just after 3 on Tuesday, while Avon Products (AVP) was down 1.4%, a neat symmetry that reflects BMO Capital Markets��take on the two companies.

Analysts Connie Maneaty and Patrick Trucchio upgraded Kimberly to Outperform today, while downgraded Avon to Underperform.

First, the good news: Maneaty and Trucchio write that they see Kimberly-Clark�� gross margin widening by 280 basis points in the second half of next year, thanks to lower commodity costs. This leads them to raise their earnings per share estimates by 25 cents and 30 cents for 2015 and 2016, respectively, and they also boosted their target price by $9 to $125.

Highlights from the note:

We think KMB will be perceived as the safest of the multinationals. Its sales outside the US are about 55% of total; this compares to 65%-70% for Procter & Gamble (PG) and Coty (COTY) and 80%-90% for Colgate (CL), Avon and Tupperware (TUP). In general, its risk to the most volatile currencies is below average (its exposure to Eastern Europe is less than 2% of sales), though it is still translating results in Venezuela (about 3% of sales and profit) at the official rate of 6.3 VEF/$ (the parallel rate just hit 175 VEF/$) and Argentina (also 3% of sales) may devalue again. The cost of important raw materials has started to weaken; as they follow oil�� decline they could boost gross margins in 2H15. Of note, polypropylene and natural gas are off 17% 4Q-to-date; pulp prices, while not declining much, seem manageable.

Hot Income Companies To Watch For 2015: ICF International Inc. (ICFI)

ICF International Inc. provides management, technology, and policy professional services to government, commercial, and international clients. It primarily offers advisory services, which include needs and market assessments, policy analysis, strategy and concept development, organizational assessment and strategy, enterprise architecture, and program design; and implementation services to manage technological, organizational, and management solutions for clients, including information technology solutions, project and program management, project delivery, strategic communications, and training. The company also provides evaluation and improvement services consisting of program evaluations, continuous improvement initiatives, performance management, benchmarking, and return-on-investment analyses. It serves energy, environment, and transportation; health, education, and social programs; and homeland security and defense. The company was formerly known as ICF Consulting Gro up Holdings, LLC and changed its name to ICF International, Inc. in 2006. The company was founded in 1969 and is headquartered in Fairfax, Virginia.

Advisors' Opinion:

• [By John Leonard]

  Key takeaways

  ICF International (ICFI) trades at an attractive multiple due to concerns that lower government spending (~three quarters of its business) will negatively affect results.However recent contract wins and an expected strong 2H mitigate these concerns.Moreover, a successful acquisition strategy reduced its dependence on government spending and resulted in significant EBITDA growth, high free cash flow and an almost 50% debt reduction.

  Company overview

Hot Safest Stocks To Watch For 2014: Chatham Lodging Trust (CLDT)

Chatham Lodging Trust is a hotel investment company. The Company was formed to invest in extended-stay, select-service and full-service hotels. The Company focuses on investing in select-service hotels, such as Courtyard by Marriott, Hampton Inn and Hampton Inn and Suites. In addition, Chatham Lodging Trust focuses on investing in branded full-service hotels. In October 2011, the Company and affiliates of Cerberus Capital Management, L.P., acquired 64 hotels from affiliates of Innkeepers USA Trust. In June 2013, Chatham Lodging Trust announced that has completed its acquisition of the 178-room Hyatt Place Pittsburgh/North Shore in Pittsburgh, Pa. Effective August 13, 2013, Chatham Lodging Trust acquired Hampton Inn & Suites, an owner and operator of hotels. In October 2013, Chatham Lodging Trust acquired Hilton Garden Inn Denver Tech Center. In November 2013, Chatham Lodging Trust acquired the 231-room Residence Inn by Marriott Seattle Bellevue/Downtown. In December 2013, Chatham Lodging Trust acquired the 160-room SpringHill Suites by Marriott Savannah Downtown/Historic District.

The Company focuses on investing primarily in hotels in the metropolitan markets in the United States. The Company has not entered into any contracts to acquire hotel properties or other assets.

Advisors' Opinion:

• [By Lauren Pollock]

  Chatham Lodging Trust(CLDT) unveiled a plan to offer at least 3.3 million shares, as the real-estate investment trust looks to raise proceeds to repay debt and help fund a portion of a property acquisition in Bellevue, Wash. Shares slipped 5.4% to $18.35 premarket.

• [By , Zacks Investment Research]

  Here are five�stocks that made it through this week’s screen:

  AmTrust Financial (AFSI) Allied World Assurance (AWH) Chatham Lodging Trust (CLDT) Federated National Holding Co. (FNHC) Whitewave Foods (WWAV)

  Get the rest of the stocks on this list and start screening for these companies on your own.

• [By Rich Duprey]

  Luxury, extended-stay hotel operator�Chatham Lodging Trust (NYSE: CLDT  ) announced this morning�its dividend for the month of June of $0.07 per share, the same rate it's paid for the past five months after switching over to a monthly payment schedule.�

Hot Safest Stocks To Watch For 2014: 1st United Bancorp Inc (FUBC)

1st United Bancorp, Inc. (Bancorp) is a financial holding company. 1st United Bank, a Florida state chartered bank, is Bancorp�� wholly owned subsidiary. The Company offers its customers, professionals, high net-worth individuals and small and medium-sized businesses, a variety of traditional loan, deposit and cash management products. As of December 31, 2010, Bancorp operated banking center from 15 locations consisting of four banking centers in Palm Beach County, four banking centers in Broward County, four banking centers in Miami-Dade County, and one banking center each in Sebastian, Vero Beach and Barefoot Bay, Florida. As of December 31, 2010, the total assets of Bancorp were at 1.268 billion and the total loans of the Company were at $847.7 million. As of December 31, 2010, its total deposits were $1.064 billion. On January 8, 2011, the Company purchased all of the assets of The Bank of Miami, National Association (The Bank of Miami). Effective April 1, 2012, the Company merged with Anderen Financial, Inc. (Anderen), under which it acquired Anderen and its subsidiary, Anderen Bank. In July 2013, 1st United Bancorp Inc completed its acquisition by merger of Enterprise Bancorp Inc (EBI) and its wholly owned subsidiary Enterprise Bank of Florida.

Investment Activity

Bancorp�� investment portfolio includes several callable agency debentures, mortgage-backed securities, adjustable rate mortgage pass-throughs, and collateralized mortgage obligations. As of December 31, 2010, the investment portfolio of the Company was at $102,289, 000.

Lending Activity

Bancorp offers a range of loans to its customers. The Company includes commercial loans, which include collateralized loans for working capital (including inventory and receivables), business expansion (including real estate construction, acquisitions and improvements), and purchase of equipment and machinery; small business loans, including small business administration (SBA) lending; Export-Im! port Bank insured or guaranteed loans; residential real estate loans to enable borrowers to purchase, refinance, construct upon or improve real property, and home equity loans, and consumer loans, including collateralized and uncollateralized loans for financing automobiles, boats, home improvements, and personal investments. As of December 31, 2010, the Company�� Commercial and Industrial loans were approximately $10.3 million, in Export Import (EXIM) loans which have either insurance or a guarantee of between 90% and 100% from the Export-Import Bank of the United States.

Through the Company�� lending division and SBA division, its commercial real estate loan portfolio includes loans secured by office buildings, warehouses, retail stores and other properties, which are located in or near the markets. Commercial real estate loans are generally originated in amounts up to 80% of the appraised value of the property securing the loan. It originates a mix of fixed rate and adjustable rate residential mortgage loans. It offers adjustable rate mortgages (ARMs), and maintains these ARMs in the portfolio or sells the ARMs in the secondary market.

The construction loan portfolio includes residential real estate, commercial real estate and homeowners��association projects. Through the business lending divisions, the Company offers real estate construction loans to individuals for the construction of their residences, to businesses and business owners primarily for owner-occupied, commercial real estate, and to homeowners��associations for general repair and/or improvements to the properties. The Company has construction loans on commercial real estate projects secured by industrial properties, office buildings or other property. The land loan portfolio includes exposure to land development, both residential and commercial. As of December 31, 2010, approximately $7.0 million or 21% of the construction and land development loan portfolio was part of the Loss Share Agreements.

T! he Company originates consumer loans bearing both fixed and prime-based variable interest rates. It originates the loans directly through the banking centers, business bankers and residential lenders. It focus the consumer lending on the origination of direct second mortgage loans and home equity loans (secured by a junior lien on residential real property), and home improvement loans. Second mortgage and home improvement loans generally originate on either a line of credit or a fixed term basis ranging from 5 to 15 years. It also extends personal loans, which may be secured by various forms of collateral, both real and personal, or to a minimal extent, on an unsecured basis.

The Company focus on the commercial loan market consists of small- to medium-sized businesses with combined borrowing needs up to $20.0 million. These businesses include professional associations (physicians, law firms, and accountants), medical services, retail trade, construction, transportation, wholesale trade, manufacturing, and tourism-related service industries. Its commercial loans are derived from the market area and underwritten on the basis of the borrowers��ability to service, such debt from recurring income. The EXIM lending operation makes loans to companies that export United States goods and services to international markets and makes loans to foreign companies to facilitate the purchase of United States goods. As of December 31, 2010, it had approximately $10.3 million in Exim loans.

Deposits

Bancorp maintains a range of deposit accounts to meet the needs of the residents and businesses in the primary service area. Products include an array of checking account programs for individuals and small businesses, including money market accounts, certificates of deposit, individual retirement account (IRA) accounts, and sweep investment capabilities. As of December 31, 2010, the Company had approximately $309.5 million in deposits by foreign nationals banking in the United States. A! s of Dece! mber 31, 2010, it had approximately $70 million in wholesale certificates of deposit.

The Company competes with Bank of America, SunTrust Bank, Wells Fargo, JP Morgan Chase & Co., BB&T, PNC, Citigroup and BankUnited, Inc.

Advisors' Opinion:

• [By Marc Bastow]

  The biggest increase among our dividend stocks this week came from Boca Raton, Florida-based financial holding company 1st United Bancorp (FUBC), who raised its quarterly dividend 100% to 2 cents per share, payable March 7 to shareholders of record as of Feb. 24.
  FUBC Dividend Yield: 1.07%

Hot Safest Stocks To Watch For 2014: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Advisors' Opinion:

• [By James E. Brumley]

  With just a quick glance at a chart of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), it would be easy to conclude it's nothing but a volatile mess. When you take a step back and look at a long-term weekly chart of RNN, however, it starts to become clear that this small cap biopharma name is on the verge of a monster-sized breakout. First things first, however.

• [By John Udovich]

  So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

• [By Roberto Pedone]

  One under-$10 biopharmaceutical player that's just starting to move into breakout territory is Rexahn Pharmaceuticals (RNN), which is engaged in the development of novel treatments for cancer to patients. This stock has been on fire so far in 2013, with shares up sharply by 62%.

  If you take a look at the chart for Rexahn Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of 36 cents per share to its intraday high of 53 cents per share. During that uptrend, shares of RNN have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RNN into breakout territory above some near-term overhead resistance levels at 49 cents to 50 cents per share. It's worth noting that volume today is tracking in extremely strong with over 3 million shares traded, versus its three-month average action of 1.22 million shares.

  Traders should now look for long-biased trades in RNN if it manages to break out above Thursday's intraday high of 53 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.22 million shares. If that breakout hits soon, then RNN will set up to re-test or possibly take out its next major overhead resistance levels at 64 cents to its 52-week high at 66 cents per share. Any high-volume move above 66 cents to 67 cents per share could then send RNN towards its next major overhead resistance levels at 81 cents per share.

  Traders can look to buy RNN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at 47 cents per share. One can also buy RNN off strength once it clears 53 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.